Briquilimab (JSP191): A Comprehensive Monograph on a Novel Anti-CD117 Monoclonal Antibody

Drug Identification and Physicochemical Properties

Nomenclature and Identifiers

Briquilimab is an investigational biotech therapeutic classified as a protein-based therapy, specifically a monoclonal antibody (mAb).[1] Its development and identification are tracked through a series of standardized nomenclature and registry numbers essential for regulatory, clinical, and research purposes. The generic name assigned to the molecule is Briquilimab.[1] The drug is cataloged in the DrugBank database under the accession number DB18136.[1]

Throughout its development history, Briquilimab has been known by several code designations and synonyms. It was initially developed under the code name AMG 191 (also styled as AMG-191 or AMG191).[1] Following its acquisition and further development by Jasper Therapeutics, it became widely known as JSP191 (also JSP 191 or JSP-191).[1] It is also referred to functionally as an anti-c-Kit monoclonal antibody.[2] These synonyms are critical for tracing the molecule's progression through preclinical and clinical stages across different sponsoring organizations.

For chemical and substance registration, Briquilimab is assigned the Chemical Abstracts Service (CAS) Number 2574591-89-0 and the Unique Ingredient Identifier (UNII) QWX84D0DRC.[1] A summary of these key identifiers is provided in Table 1.

Table 1: Key Identifiers and Properties of Briquilimab

Structural and Molecular Characterization